CMAB015 (secukinumab biosimilar) / Mabpharm Limited - LARVOL DELTA

Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers (clinicaltrials.gov) - P1 | N=114 | Not yet recruiting | Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd

New P1 trial • Dermatology • Immunology • Psoriasis

Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - P3 | N=336 | Active, not recruiting | Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd | Trial completion date: Dec 2025 ➔ Mar 2026 | Recruiting ➔ Active, not recruiting

Enrollment closed • Trial completion date • Dermatology • Immunology • Psoriasis

Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - P3 | N=336 | Recruiting | Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Immunology • Psoriasis

A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx® in Healthy Chinese Male Subjects. (PubMed, Drug Des Devel Ther) - P1 | "NCT05734482) and Chinadrugtrials.org.cn (Identifier No. CTR20230105)."

Clinical • Journal • P1 data • PK/PD data • Ankylosing Spondylitis • Dermatology • Hidradenitis Suppurativa • Idiopathic Arthritis • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis

Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - P3 | N=336 | Not yet recruiting | Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd

New P3 trial • Dermatology • Immunology • Psoriasis